Vertex Pharmaceuticals presented positive long-term data on CASGEVY™ at the 2024 EHA Congress. The results confirm consistent and durable clinical benefits for patients with severe SCD or TDT, aligning with previous primary and key secondary endpoints analyses.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing